Menu
Currency
GWAS Study

Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.

Purrington KS, Slager S, Eccles D et al.

24325915 PubMed ID
GWAS Study Type
8385 Participants
49 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

PK
Purrington KS
SS
Slager S
ED
Eccles D
YD
Yannoukakos D
FP
Fasching PA
MP
Miron P
CJ
Carpenter J
CJ
Chang-Claude J
MN
Martin NG
MG
Montgomery GW
KV
Kristensen V
AH
Anton-Culver H
GP
Goodfellow P
TW
Tapper WJ
RS
Rafiq S
GS
Gerty SM
DL
Durcan L
KI
Konstantopoulou I
FF
Fostira F
VA
Vratimos A
AP
Apostolou P
KI
Konstanta I
KV
Kotoula V
LS
Lakis S
DM
Dimopoulos MA
SD
Skarlos D
PD
Pectasides D
FG
Fountzilas G
BM
Beckmann MW
HA
Hein A
RM
Ruebner M
EA
Ekici AB
HA
Hartmann A
SR
Schulz-Wendtland R
RS
Renner SP
JW
Janni W
RB
Rack B
SC
Scholz C
NJ
Neugebauer J
AU
Andergassen U
LM
Lux MP
HL
Haeberle L
CC
Clarke C
PN
Pathmanathan N
RA
Rudolph A
FD
Flesch-Janys D
NS
Nickels S
OJ
Olson JE
IJ
Ingle JN
OC
Olswold C
SS
Slettedahl S
EJ
Eckel-Passow JE
AS
Anderson SK
VD
Visscher DW
CV
Cafourek VL
SH
Sicotte H
PN
Prodduturi N
WE
Weiderpass E
BL
Bernstein L
ZA
Ziogas A
IJ
Ivanovich J
GG
Giles GG
BL
Baglietto L
SM
Southey M
KV
Kosma VM
FH
Fischer HP
RM
Reed MW
CS
Cross SS
DS
Deming-Halverson S
SM
Shrubsole M
CQ
Cai Q
SX
Shu XO
DM
Daly M
WJ
Weaver J
RE
Ross E
KJ
Klemp J
SP
Sharma P
TD
Torres D
RT
Rüdiger T
WH
Wölfing H
UH
Ulmer HU
FA
Försti A
KT
Khoury T
KS
Kumar S
PR
Pilarski R
SC
Shapiro CL
GD
Greco D
HP
Heikkilä P
AK
Aittomäki K
BC
Blomqvist C
IA
Irwanto A
LJ
Liu J
PV
Pankratz VS
WX
Wang X
SG
Severi G
MA
Mannermaa A
ED
Easton D
HP
Hall P
BH
Brauch H
CA
Cox A
ZW
Zheng W
GA
Godwin AK
HU
Hamann U
AC
Ambrosone C
TA
Toland AE
NH
Nevanlinna H
VC
Vachon CM
CF
Couch FJ
Chapter II

Abstract

Summary of the research findings

Triple-negative (TN) breast cancer is an aggressive subtype of breast cancer associated with a unique set of epidemiologic and genetic risk factors. We conducted a two-stage genome-wide association study of TN breast cancer (stage 1: 1529 TN cases, 3399 controls; stage 2: 2148 cases, 1309 controls) to identify loci that influence TN breast cancer risk. Variants in the 19p13.1 and PTHLH loci showed genome-wide significant associations (P < 5 × 10(-) (8)) in stage 1 and 2 combined. Results also suggested a substantial enrichment of significantly associated variants among the single nucleotide polymorphisms (SNPs) analyzed in stage 2. Variants from 25 of 74 known breast cancer susceptibility loci were also associated with risk of TN breast cancer (P < 0.05). Associations with TN breast cancer were confirmed for 10 loci (LGR6, MDM4, CASP8, 2q35, 2p24.1, TERT-rs10069690, ESR1, TOX3, 19p13.1, RALY), and we identified associations with TN breast cancer for 15 additional breast cancer loci (P < 0.05: PEX14, 2q24.1, 2q31.1, ADAM29, EBF1, TCF7L2, 11q13.1, 11q24.3, 12p13.1, PTHLH, NTN4, 12q24, BRCA2, RAD51L1-rs2588809, MKL1). Further, two SNPs independent of previously reported signals in ESR1 [rs12525163 odds ratio (OR) = 1.15, P = 4.9 × 10(-) (4)] and 19p13.1 (rs1864112 OR = 0.84, P = 1.8 × 10(-) (9)) were associated with TN breast cancer. A polygenic risk score (PRS) for TN breast cancer based on known breast cancer risk variants showed a 4-fold difference in risk between the highest and lowest PRS quintiles (OR = 4.03, 95% confidence interval 3.46-4.70, P = 4.8 × 10(-) (69)). This translates to an absolute risk for TN breast cancer ranging from 0.8% to 3.4%, suggesting that genetic variation may be used for TN breast cancer risk prediction.

1,529 European ancestry cases, 3,399 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

8385
Total Participants
GWAS
Study Type
Yes
Replicated
2,148 European ancestry cases, 1,309 European ancestry controls
Replication Participants
European
Ancestry
Finland, U.S., Australia, Germany, U.K., Greece, Norway
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.